References

Citations

1. Beers MH, et al., eds. (2004). Merck Manual of Health and Aging. Whitehouse Station, NJ: Merck Research Laboratories.

2. Alzheimer's Association (2007). Symptoms of Alzheimer’s. Available online: http://www.alz.org/alzheimers_disease_symptoms_of_alzheimers.asp.

3. Espeland MA, et al. (2004). Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative memory study. JAMA, 291(24): 2959–2968.

4. Shumaker SA, et al. (2004). Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative memory study. JAMA, 291(24): 2947–2958.

5. Wang L, et al. (2006). Performance-based physical function and future dementia in older people. Archives of Internal Medicine, 166(10): 1115–1120.

6. Wilson RS, et al. (2002). Participation in cognitively stimulating activities and risk of incident Alzheimer disease. JAMA, 287(6): 742–748.

7. Wilson RS, et al. (2007). Relation of cognitive activity to risk of developing Alzheimer disease. Neurology, 69(20): 1911–1920.

8. Barberger-Gateau P, et al. (2007). Dietary patterns and risk of dementia: The three-city cohort study. Neurology, 69(20): 1921–1930.

9. Sofi F, et al. (2008). Adherence to Mediterranean diet and health status: Meta-analysis. BMJ. Published online September 11, 2008 (doi:10.1136/bmj.a1344).

10. Tariot PN, et al. (2004). Memantine treatment in patients with moderate to severe Alzheimer's disease already receiving donepezil. JAMA, 291(3): 317–324.

11. Sink KM, et al. (2005). Pharmacological treatment of neuropsychiatric symptoms of dementia: A review of the evidence. JAMA, 293(5): 596–608.

12. Trinh NH, et al. (2003). Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: A meta-analysis. JAMA, 289(2): 210–216.

13. Raina P, et al. (2008). Effectiveness of cholinesterase inhibitors and memantine for treating dementia: Evidence review for a clinical practice guideline. Annals of Internal Medicine, 148(5): 379–397.

14. Howard RJ, et al. (2007). Donepezil for the treatment of agitation in Alzheimer's disease. New England Journal of Medicine, 357(14): 1382–1392.

15. Warner J, et al. (2008). Dementia, search date February 2006. Online version of BMJ Clinical Evidence. Also available online: http://clinicalevidence.com.

16. Ballard CG, et al. (2002). Aromatherapy as a safe and effective treatment for the management of agitation in severe dementia: The results of a double-blind placebo-controlled trial with Melissa. Journal of Clinical Psychiatry, 63(7): 553–558.

Other Works Consulted

• California Workgroup on Guidelines for Alzheimer’s Disease Management (2008). Guideline for Alzheimer’s disease management. Chicago: Alzheimer’s Association. Available online: http://www.alz.org/californiasouthland/documents/professional_GuidelineFullReport.pdf.

• Desai AK, Grossberg GT (2005). Diagnosis and treatment of Alzheimer's disease. Neurology, 64(Suppl 3): S34–S39.

• National Center for Health Statistics (2008). Alzheimer's Disease. Available online: http://www.cdc.gov/nchs/fastats/alzheimr.htm.

• Petersen RC, et al. (2001, reaffirmed 2003). Practice parameter: Early detection of dementia: Mild cognitive impairment (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology, 56(9): 1133–1142.

• Small SA, Mayeux R (2005). Alzheimer disease and related dementias. In LP Rowland, ed., Merritt's Neurology, 11th ed., pp. 771–780. Philadelphia: Lippincott Williams and Wilkins.